BIG
CLDX icon

Brooklyn Investment Group’s Celldex Therapeutics CLDX Stock Holding History

Brooklyn Investment Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-538
Closed -$10.9K – 1059
2025
Q2 		$10.9K Buy
+538
New +$10.5K ﹤0.01% 2129
2025
Q1 		– Sell
-98
Closed -$2.48K – 2788
2024
Q4 		$2.48K Buy
+98
New +$2.66K ﹤0.01% 1401

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brooklyn Investment Group's CLDX Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 538 shares — an estimated $10.9K sold.

Brooklyn Investment Group first reported a position in CLDX in Q4 2024 and held it in 2 quarters. The position peaked at $10.9K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 538 Celldex Therapeutics shares in Q3 2025, an estimated $10.9K.
  • Brooklyn Investment Group first reported a position in Celldex Therapeutics in Q4 2024 and held it in 2 quarters.
  • Brooklyn Investment Group's Celldex Therapeutics position peaked at $10.9K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.